API AND DRUG DEVELOPMENT PROJECT

Pharma Holdings AS is a privately owned biopharmaceutical company with offices in Oslo and Tromsø, Norway. Pharma Holdings AS develops novel drugs for treatment of microbial (bacterial, fungal and virus) infections. LTX-109 is the active ingredient in our pharmaceutical drug. The manufacturing of LTX-109 is a complicated multi-phase protect, starting with small scale laboratory production and ending in a large scale production. The API AND DRUG DEVELOPMENT PROJECT is divided into three parts, and the primary objective are: Development of new methods for manufacturing LTX-109 to be used in pre-clinical and early-clinical Trials. Manufacture and up-scaling development of LTX-109 to be used in late stage clinical trials. Development and production of a nasal drug solution (nasal spray) to be used in clinical trials on upper respiratory infections.